TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06587399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy treatment
Description: Joint mobilization techniques will be applied to the shoulder joint complex, adapted to the subjects' degree of irritability.~The muscular trigger points of the shoulder muscles will be treated using a pressure release technique applied for 60 seconds.~In addition, the subjects will carry out a 12-week home-based therapeutic exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial shock wave treatment
Description: The treatment will be carried out with 1 session per week for 6 weeks. For this purpose, a radial shock wave generator will be used, at a frequency of 8 to 12 Hz, 2000 pulses/session and with a pressure of 2.5 to 4.0 bar.~Between 3 and 5 points will be treated per session: insertion of the supraspinatus muscle, dorsolateral area under the acromion and a maximum of 3 trigger points of the rotator cuff muscles.~In addition, the subjects will carry out a 12-week home therapeutic exercise program.
Study: NCT06528548

Intervention type: DIAGNOSTIC_TEST
Intervention: DBS card
Description: Collection of a second DBS card

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Blood samples taken from child and parents
Study: NCT05312645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac 1% Topical
Description: 2 grams topically four times daily for 2 weeks to posterior cervical spine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum Jelly
Description: 2 grams topically four times daily for 2 weeks to posterior cervical spine
Study: NCT06672549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally. ISA specific interventions will be listed in the ISA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally. ISA specific interventions will be listed in the ISA.
Study: NCT06004037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delpazolid
Description: Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total.
Study: NCT05588128

Intervention type: DRUG
Intervention: 18F-DCFpyL
Description: Administered to Cohort.
Study: NCT06619574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Analysis Group
Description: Dental Compass and Dental Compass software used for therapeutic splint fabrication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Analysis Cohort
Description: Manual methods used for therapeutic splint fabrication
Study: NCT06673758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tai chi exercises
Description: tai chi exercises of three basic levels will be given with sessions of two weeks five time a day and follow efftects of tai chi exercises by 6minute walk test and time up and go test and check the results before and after exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Art and crafts activity
Description: Art and crafts activity will be given to control group and check cardiorespiratory fitness before and after arts and crafts activity
Study: NCT06071013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
Description: Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells.
Study: NCT06683664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated health service delivery for very young adolescents
Description: The proposed HPV-PASSREV intervention will aim to increase adolescent-centered access to HPV vaccination and other very young adolescent health services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health facility and community levels.
Study: NCT06682910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microtech sensor pressure
Description: Microtech sensor implantation
Study: NCT06683755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV
Study: NCT06684522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG
Description: Upadacitinib 15mg daily
Study: NCT06683235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.
Study: NCT06684587

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: In this 10-week intervention, participants will be given strengthening exercises and neuromuscular re-education exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Exercise
Description: In this 10-week intervention, mindfulness meditation will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis.
Study: NCT06685172

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: f-ESWT
Description: In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: r-ESWT
Description: In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
Study: NCT06682065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine for contraceptive counseling (TECC)
Description: WhatsApp algorithmic chatbot that screens preferences and medical eligibility to recommend two methods, informs about all methods, allows choice out of all methods, produce summary to substitute for clinical record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: In-personcontraceptive counseling with a nurese according to clinical standard of care
Study: NCT06682052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-stress ball
Description: The women will be given a round, silicone, medium-sized and medium-hard anti-stress ball, and they will be told how to use the stress ball, and they will be asked to squeeze the anti-stress ball throughout the examination, allowing the patients to rest occasionally as they wish. The women will be told to count to 3 as they squeeze the anti-stress ball, then to relax the stress ball and repeat this process.
Study: NCT05588505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD
Description: The intervention is 12 weeks long, made up of one 2- hour session each week. These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills. These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
Study: NCT05574036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat 80 MG Oral Tablet
Description: Febuxostat used as 80 mg oral tablet once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vit E
Description: Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
Study: NCT06691867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-STRONG
Description: I-STRONG is an evidence-based protocol from the FIT Teens program. This intervention combines mind-body and cognitive-behavioral approaches with neuromuscular movement training informed by pediatric sports medicine and injury prevention research. It aims to teach mind-body skills applicable during movement training to enhance psychological coping and reduce fear of pain and activity avoidance.~I-STRONG consists of 16 group-based telehealth sessions held twice weekly over 8 weeks. Each group can accommodate up to 6 patients with SCD. Adolescents are expected to attend all sessions, while parents will attend 6 of the 16. Parents will receive education about I-STRONG, guidance on supporting their teen's behavior change, and opportunities for networking with other parents of youth with SCD. Sessions will include brief daily homework (e.g., using phone apps to practice skills) to facilitate proficiency. Participants will self-report their practice of assigned skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care (EUC)
Description: The EUC arm is designed to account for potential effects on time and standard medical care outcomes. Patients randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months (i.e., time from enrollment through 6-month post-treatment assessment) before starting the intervention program to coincide with the study duration of the ES arm. After completing the 6-month follow-up assessment, patients will have the opportunity to start the I-STRONG for SCD intervention.
Study: NCT06692348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study: NCT05817006

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Device
Description: research of the long-COVID-19 in the children
Study: NCT06693843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
Study: NCT06703021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 or Placebo
Description: Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
Study: NCT06465290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor relearning training with wearable ankle robot
Description: Ankle motor control relearning training under real-time feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive stretching with wearable ankle robot
Description: Passive stretching under intelligent robotic control
Study: NCT06283030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation
Description: Device-mediated stimulation of the hypoglossal nerve
Study: NCT05438420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q702
Description: The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q702
Description: The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
Study: NCT05639205

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Flow Device
Description: Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
Study: NCT05343507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketalar 50 MG/ML Injectable Solution
Description: Intravenous solution (other info already provided)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Solution
Study: NCT05545488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: I had the women wear virtual reality glasses and watch the video they wanted for at least 5, maximum 15 minutes during the examination.
Study: NCT06310109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICU diary
Description: .The PICU diary is a notebook with lined sheets located at the patient's bedside. In this diary parents, other caregivers, family members, healthcare professionals or other visitors can write thoughts, report events related to the child/adolescent's admission, attach drawings or photographs for the patient or related to the PICU admission.
Study: NCT04725643

Intervention type: DEVICE
Intervention: Track bleeding patterns before and after implant
Description: Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
Study: NCT06193629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lang Qingata
Description: Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
Study: NCT05931900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients
Description: Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
Study: NCT05634928

Intervention type: OTHER
Intervention: collection data
Description: collection data
Study: NCT04621760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Decision Support Tool (DST)
Description: The tool is founded on principles of decision-science and developed in a systematic manner including pilot testing. The tool will present HIV prevention information through a tablet in the clinical setting. The decision support tool will address barriers to PrEP delivery, including 1) limited client knowledge about PrEP, 2) limited time to educate patients in busy clinics, 3) women's lack of knowledge of their own HIV vulnerability, and 4) hesitancy of women to initiate discussions about PrEP with providers due to judgmental attitudes and stigma. Also, the tool emphasizes the highly variable and individual nature of baseline risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Participants in this arm will receive usual care.
Study: NCT05234333

Intervention type: DRUG
Intervention: SARS-CoV-2 vaccine
Description: SARS-CoV-2 vaccination

Intervention type: DRUG
Intervention: SARS-CoV-2 vaccine
Description: SARS-CoV-2 vaccination
Study: NCT04942873

Intervention type: OTHER
Intervention: adherence
Description: PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin

Intervention type: OTHER
Intervention: adherence
Description: PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin

Intervention type: OTHER
Intervention: adherence
Description: PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
Study: NCT06256874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Training
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT05065138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized training on Helicobacter pylori eradication treatment
Description: Standardized training on Helicobacter pylori eradication treatment
Study: NCT05939609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ballistic Stretching Exercise
Description: It will be applied 4 times a week for 6 weeks and before starting on-water training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extender Exercise
Description: It will be applied 4 times a week for 6 weeks and before starting on-water training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: It will be applied 4 times a week for 6 weeks and before starting on-water training.
Study: NCT06433063

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F-MISO PET
Description: Evaluation of tumor hypoxia with F-MISO PET
Study: NCT06502080

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative radiotherapy
Description: Consolidative radiotherapy: total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
Description: Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab

Intervention type: DRUG
Group type: OTHER
Intervention: Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
Description: Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
Study: NCT06194669

Intervention type: OTHER
Intervention: Blood and urine sample collection
Description: One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected

Intervention type: OTHER
Intervention: Blood and urine sample collection
Description: One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
Study: NCT04922762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity, Normal Volume Exercise Training
Description: Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity, Normal Volume Exercise Training
Description: Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity, High Volume Exercise Training
Description: Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum
Study: NCT05740384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonotubometry Assessment
Description: The exact order of the measurements will be randomised:~* Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~* This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes.